1ST Biotherapeutics Inks ~$314.8M Deal with SK Biopharmaceuticals for 1ST-104

Shots: 1ST Biotherapeutics SK Biopharmaceuticals have entered into an exclusive global licensing agreement & strategic equity investment partnership to advance 1ST-104 for the treatment of Parkinson's disease As per the deal, 1STBIO will receive a $1.8M upfront payment, with the licensing agreement valued at ~$314.8M, incl. a $1.8M short-term milestone upon candidate selection & additional…

ByRidhi RastogiSeptember 18, 2026

Biohaven Licenses Kv7 Epilepsy Platform to SK Biopharmaceuticals in $795M Deal

Shots: Biohaven has granted SK Biopharmaceuticals exclusive worldwide rights to its Kv7 ion channel platform, led by opakalim (BHV-7000), a P-II/III candidate for focal epilepsy, with RISE3 topline results are expected in H2’26 Biohaven will receive upfront & milestone payments up to $795M for the Kv7 platform, incl. $400M in cash ($350M at closing &…

ByRidhi RastogiAugust 26, 2026

Insilico Medicine and SK Biopharmaceuticals Sign AI-Driven Drug Discovery Deal Worth Up to $2.5B for Neuroimmune Disorders

Shots: Insilico Medicine and SK Biopharmaceuticals entered a research and development collaboration to discover AI-enabled therapies for neuroimmune disorders of the central nervous system (CNS), including neuroinflammatory, neurodegenerative, and rare neurological diseases Under the agreement, Insilico will utilize its proprietary Pharma.AI platform, covering target validation, generative chemistry, and molecule optimization, alongside its preclinical drug discovery…

ByPrince GiriJune 22, 2026

1ST Biotherapeutics Inks ~$314.8M Deal with SK Biopharmaceuticals for 1ST-104

Biohaven Licenses Kv7 Epilepsy Platform to SK Biopharmaceuticals in $795M Deal

Insilico Medicine and SK Biopharmaceuticals Sign AI-Driven Drug Discovery Deal Worth Up to $2.5B for Neuroimmune Disorders

Contact US

FOLLOW US